Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease

This study has been completed.
Sponsor:
Collaborator:
Allergan
Information provided by (Responsible Party):
Rodney U Anderson, Stanford University
ClinicalTrials.gov Identifier:
NCT01421719
First received: August 19, 2011
Last updated: August 22, 2011
Last verified: August 2011
  Purpose

The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD. In the over-65 year old age group, where 1% of men suffer from this disease, they are also prone to development of benign prostatic hyperplasia (BPH) and consequent associated lower urinary tract dysfunction. Similarly the over 65-year age group develop spontaneous overactive bladder up to a prevalence of 30% of both men and women. The urologic disorder is exceedingly devastating in reducing the quality of life in these individuals due to the lower urinary tract symptoms and ultimate urinary incontinence in a high proportion of patients.

While attempts at pharmacologic treatment are partially satisfactory many patients are intolerant of oral drugs.

Botulinum-A neurotoxin (BTX-A) has been shown in pilot trials to be quite effective in reducing overactive bladder symptoms and is specifically beneficial for a wide-variety of neurogenic bladder causes of over activity . The treatment procedure of injecting the detrusor muscle of the bladder with BTX-A is quite simple, does not impose significant risks to the patient, and can be performed as an office urologic procedure.

This pilot clinical trial intends to demonstrate the safety and efficacy of low-dose Botox-A injections into the bladder to improve urinary symptoms in 20 patients.


Condition Intervention Phase
Parkinson's Disease
Neurogenic Bladder
Urinary Incontinence
Clostridium Botulinum Toxin Adverse Reaction
Drug: Cystoscopic injection of Botox into the urinary bladder
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Onabotulinum Toxin Type A (BTX-A) For Treatment of Neurogenic Overactive Bladder Due to Parkinson's Disease: Safety and Efficacy

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Safety and feasibility of Botox A urinary bladder injection in Parkinson's pts [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
    Tolerability of office local injection of low dose drug, risk of urinary retention, infection, bleeding or significant pain.


Secondary Outcome Measures:
  • Efficacy of low-dose urinary bladder Botox A injection on PD patient symptoms [ Time Frame: 6 months ] [ Designated as safety issue: No ]
    Specific measurements of 3-day voiding diaries, King's Health Questionnaire, urinary flow rates and residual urine to determine efficacy on undesirable lower urinary tract symptoms.


Enrollment: 20
Study Start Date: February 2009
Study Completion Date: July 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: botulinum toxin treatment
Injection of Botox into urinary bladder for neurogenic symptoms.
Drug: Cystoscopic injection of Botox into the urinary bladder
100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
Other Name: Botox A (Allergan, Inc)

Detailed Description:

This open-label pilot study will evaluate the safety and efficacy of intra-detrusor injections of botulinum-A toxin (BTX-A) in 20 male or female patients with Parkinson's disease and neurogenic overactive bladder with or without urinary incontinence, but without evidence of significant urinary retention (>25% of bladder capacity at void).

Patients will be invited to participate based upon subjective symptoms of uncontrolled lower urinary tract urgency, frequency and urinary incontinence. Only patients who have a Hoehn and Yahr Stage IV or better (or UPDRS equivalent) will be considered. Patients must have tried anti-muscarinic agents and failed to improve or were intolerant of these pharmacologic agents. Oral anti-muscarinic medications will be discontinued two weeks prior to urodynamics testing and treatment visit. At baseline urinary symptom scores will be obtained using The King's Health Questionnaire (KHQ, a validated scoring system for urinary symptoms) and the AUA Urinary Symptom Score. In addition a 3-day fluid intake and urinary outflow timed voiding diary will be submitted at the time of testing and treatment as well as follow-up visits.

After signing an informed consent and meeting all inclusion and exclusion criteria, patients will be tested with urodynamic studies to determine current lower urinary tract neurophysiologic functioning. A "free-flow" urinary flow rate and post-void residual urine volume test will be performed as well as filling cystometrogram and pressure/flow measurement. Patients with evidence of outlet obstruction (high pressure/low flow) will be excluded from the study. Only patients with a post-void residual urine volume less than or equal to 25% of the total bladder volume at void will be included. No catheters or other measurement devices will be attached to the body at the time of the initial free urinary flow and post-void urine volume measurement. A repeat pressure/flow determination will be performed during the urodynamics cystometrogram.

After qualification to proceed, patients will then be transferred to the adjoining cystoscopy suite. Pre-procedure oral sedation and analgesia will be given. Subjects will undergo cystoscopy under topical lidocaine anesthesia and undergo 25-gauge needle injections of BTX-A. BTX-A treatment for each participant will be limited to a total dose of 100 units in a minimum of 10 to 20 locations. Any patient unable to void after the procedure will receive an indwelling catheter for 24 hours. Patients will be contacted by telephone within 24-48 hours after the procedure for safety assessment. Follow-up clinic visit evaluations will occur at 1 month, 3 months, 6 months and 9 months. A 3-day voiding diary, King's Health Questionnaire, AUA Symptom Score sheet and Global Response Assessment (GRA) Questionnaire will be collected at each follow-up visit. Incontinence will be documented on this diary. Uroflowmetry and post-void residual volume will also be assessed at each follow-up visit.

  Eligibility

Ages Eligible for Study:   50 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:•

  • Male or female subjects, 50 to 85 years of age.
  • Patients diagnosed with Parkinson's disease prior to lower urinary tract symptoms.
  • Documentation of low volume desire to void and/or unstable detrusor contractions with or without incontinence on cystometrogram. Voiding diary consistent with overactive bladder
  • Written informed consent has been obtained.
  • Ability to follow study instructions and likely to complete all required visits.
  • Written authorization for Use and Release of Health and Research Study Information has been obtained.
  • Subject has minimum to moderate severity/stage of disease, Hoehn and Yahr stage IV or less (or UPDRS equivalent)
  • Usual and customary medications allowed

Exclusion Criteria:

  • Uncontrolled clinically significant medical condition other than the condition under evaluation
  • Known allergy or sensitivity to any of the components in the study medication.
  • Concurrent participation in another investigational drug or device study or participation within 60 days period of time prior to study
  • New anticholinergic medication. Should discontinue any anti-muscarinic medication 14 days prior to injection.
  • Treatment with botulinum toxin of any serotype prior to enrollment in study (if applicable).
  • Any medical condition that may put the subject at increased risk with exposure to BTX-A including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other disorder that might interfere with neuromuscular function (if applicable).
  • Evidence of alcohol, drug abuse or other relevant neuropsychiatric condition (if applicable)
  • Urinary tract infection
  • Significant BPH with evidence of severe bladder trabeculation
  • Greater than 50% post-void residual urine volume
  • Any condition or situation that, in the investigator's opinion, may put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01421719

Locations
United States, California
Stanford University Hospital and Clinics
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Allergan
Investigators
Principal Investigator: Rodney U Anderson, MD Stanford University
  More Information

No publications provided

Responsible Party: Rodney U Anderson, Professor of Urology, Stanford University
ClinicalTrials.gov Identifier: NCT01421719     History of Changes
Other Study ID Numbers: 000124
Study First Received: August 19, 2011
Last Updated: August 22, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Stanford University:
Parkinson's Disease
Neurogenic Bladder
Urinary Incontinence
botulinum toxin
cystoscopy
Effect of Other Parasympatholytics [Anticholinergics and Antimuscarinics] and Spasmolytics

Additional relevant MeSH terms:
Urinary Bladder, Neurogenic
Parkinson Disease
Urinary Incontinence
Neurologic Manifestations
Nervous System Diseases
Urinary Bladder Diseases
Urologic Diseases
Signs and Symptoms
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Urination Disorders
Lower Urinary Tract Symptoms
Urological Manifestations
Botulinum Toxins
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 31, 2014